Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
  • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
  • A61J1/035—Blister-type containers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
  • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
  • C07D209/49—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide and having in the molecule an acyl radical containing a saturated three-membered ring, e.g. chrysanthemumic acid esters
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/64—One oxygen atom attached in position 2 or 6
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/73—Unsubstituted amino or imino radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/81—Amides; Imides
  • C07D213/82—Amides; Imides in position 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/84—Nitriles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/18—One oxygen or sulfur atom
  • C07D231/20—One oxygen atom attached in position 3 or 5
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention features modulators of Cystic Fibrosis Transmembrane
• CTR Conductance Regulator
• Cystic fibrosis is a recessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 children and adults in Europe. Despite progress in the treatment of CF, there is no cure.
• the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as F508del. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease.
• Ring A is a C6-C10 aryl ring; C3-C 10 cycloalkyl ring; or a C3-C14 heteroaryl or
• heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring B is a C3-C 10 cycloalkyl ring; a C6-C10 aryl ring; or a C4-C 10 heteroaryl or
• heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring C is a C6-C 10 aryl ring; a C3-C 14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, NR, O, or S; or a C3-C10 cycloalkyl ring;
• W is O. NR, or S;
• X is O or NR
• Y is independently CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Z is NR or CHR
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or
• fluoroalkoxy C1-C6 alkenyl; CI-C6 alkynyl; (C1-C9 alkylene)-R 4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl ;C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are optionally and independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; OH; C0 2 R; C1-C6 alkyl or fluoroaikyl; C1-C6 alkenyl; CI-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; CC R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH;C0 2 H; C0 2 C1-C6 alkyl; CI-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• o is O, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3;
• q O, 1, 2, 3, 4, or 5;
• HI! is a single bond or a double bond
• the present invention also features pharmaceutical compositions thereof, which may include additional agents, and methods of treating CFTR mediated diseases, such as cystic fibrosis, comprising administering compounds of formula I to a subject in need thereof.
• the present invention also features kits comprising compounds of formula I.
• Figure 1 discloses a list of CFTR mutations by name, protein name, and legacy name that in one aspect of the invention a patient may possess and be treatable by the compounds and compositions of the present invention.
• CFTR cystic fibrosis transmembrane conductance regulator
• mutants can refer to mutations in the CFTR gene or the CFTR protein.
• a “CFTR mutation” refers to a mutation in the CFTR gene, and a “CFTR mutation” refers to a mutation in the CFTR protein.
• a "F508del mutaion” or “F508del” is a specific mutation within the CFTR protein.
• the mutation is a deletion of the three nucleotides that comprise the codon for amino acid phenylalanine at position 508, resulting in CFTR protein that lacks this phenylalanine residue.
• CFTR gating mutation means a CFTR mutation that results in the production of a CFTR protein for which the predominant defect is a low channel open probability compared to normal CFTR (Van Goor, F., Hadida S. and Grootenhuis P.,
• Gating mutations include, but are not limited to, G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S 1251N. S 1255P, and G1349D.
• a patient who is "homozygous" for a particular mutation e.g. FS08del, has the same mutation on each allele.
• F508del has this mutation on one allele, and a different mutation on the other allele.
• a modulator refers to a compound that increases the activity of a biological compound such as a protein.
• a CFTR modulator is a compound that increases the activity of CFTR.
• the increase in activity resulting from a CFTR modulator may be through a corrector mechanism or a potentiator mechanism as described below.
• CFTR corrector refers to a compound that increases the amount of functional CFTR protein to the cell surface, resulting in enhanced ion transport.
• CFTR potentiator refers to a compound that increases the channel activity of CFTR protein located at the cell surface, resulting in enhanced ion transport.
• inducing refers to increasing CFTR activity, whether by the corrector, potentiator, or other mechanism.
• active pharmaceutical ingredient or “API” refers to a biologically active compound.
• a "patient,” “subject” or “individual” are used interchangeably and refer to either a human or non-human animal.
• the term includes mammals such as humans.
• ⁇ dose or “effective amount” are used interchangeably herein and refer to that amount that produces the desired effect for which it is administered (e.g., improvement in CF or a symptom of CF or lessening the severity of CF or a symptom of CF).
• amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and
• treatment generally mean the improvement of CF or its symptoms or lessening the severity of CF or its symptoms in a subject.
• 'Treatment includes, but is not limited to, the following: increased growth of the subject, increased weight gain, reduction of mucus in the lungs, improved pancreatic and/or liver function, reduced cases of chest infections, and/or reduced instances of coughing or shortness of breath. Improvements in or lessening the severity of any of these conditions can be readily assessed according to standard methods and techniques known in the art.
• the term "in combination with” when referring to two or more compounds or agents means that the order of administration includes the compounds or agents being administered prior to, concurrent with, or subsequent to each other to the patient.
• compounds within the compositions of the invention can optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention (such as the compounds listed in Table 1).
• substituents such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention (such as the compounds listed in Table 1).
• -R»in formulae I-Id-ii encompass specific groups, such as, for example, alky], alkenyl, alkynyl, alkoxy, heteroaryl, heterocyclic, cycloalkyl, and aryl, etc.
• each of the specific groups for the variables R1-R can be optionally substituted with one or more group selected from halo, phospho, OH, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, fluoroalkyl, alkyl, alkenyl, alkynyl, nitro, CN, hydroxyl, and (Cl-C9alkylene)-E wherein up to 4 C3 ⁇ 4 units are independently replaced with O, S, SO2, SO, CO, NH, iV-alkyl, iV-alkenyl, or iV-alkynyl, and E is H, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkoxy.CN, or CF3, further wherein each of the aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is optionally substituted with one or more group selected from halo, alkyl, amino, CN, alkeny
• a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
• substituents or variables can be selected from more than one specific group.
• one specific group for a variable may include or overlap with another specific group for the same variable, the narrower specific group is provisoed out from the broader specific group. In other words, double inclusion cannot exist.
• substituted refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
• substituents are described above in the definitions and below in the description of compounds and examples thereof.
• an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with mote than one substituent selected from a specified group, the substituent can be either the same or different at every position.
• substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
• “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
• adjacent refers to positions on the ring wherein the two ring atoms are bonded to each other. Two ring atoms with an intervening ring atom are not considered adjacent even when that intervening atom does not allow substitution due to valency.
• aliphatic means a straight-chain (i.e., unbranched) or branched hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups.
• spiro means a two-ring system wherein both rings share only one common atom.
• cycloaliphatic or "cycloalkyl” mean a monocyclic, bicyclic (fused or spiro), tricyclic (fused or spiro), or propellane hydrocarbon that has a single point of attachment to the rest of the molecule, and that is completely saturated or contains one or more units of unsaturation, but none of the individual rings in the monocyclic, bicyclic, or tricyclic
• hydrocarbon is aromatic.
• the single point of attachment can be on the saturated or unsaturated carbon.
• cycloaliphatic or “cycloalkyl” refers to a monocyclic C3-C8 hydrocarbon or bicyclic Cg-Ci2 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but none of the individual ring in the monocyclic Cj-Cg hydrocarbon or fused bicyclic Cg-C hydrocarbon is aromatic, and that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
• an "alkyl” group refers to a saturated hydrocarbon group containing 1- 20 (e.g., 1-6 or 1- 12) carbon atoms.
• An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl.
• an "alkenyl” group refers to a hydrocarbon group that contains 2-20 (e.g., 2-12, 2-6, or 2- ) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. The point of attachement can be on a saturated carbon or unsaturated carbon. Examples of an alkenyl group include, but are not limited to allyl, isoprenyl, 2-butenyl, and 2-hexenyl.
• an "alkynyl” group refers to a hydrocarbon group that contains 2-20 (e.g., 2- 12, 2-6, or 2-4) carbon atoms and has at least one triple bond.
• An alkynyl group can be straight or branched. The point of attachement can be on a saturated carbon or unsaturated carbon. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl.
• an "alkoxy” group refers to -O-alkyl, O-alkenyl, or O-alknyl, wherein alkyl, alkenyl, and alkynyl are as defined above.
• fluoroalky or fluoroalkoxy refers to alkyl or alkoxy wherein one or more hydrogen is substituted with a fluoro.
• amino refers to N3 ⁇ 4 which is optionally substituted with one or two groups independently selected from alkyl, cycloalkyl, and heterocycloalkyl.
• electronegative group means an atom or a group that is electronegative relative to hydrogen. See, e.g., “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure," Jerry March, 4 lh Ed., John Wiley & Sons (1992), e.g., pp. 14-16, 18-19, etc. Exemplary such substituents include halo such as CI, Br, or F, CN, COOH, CF 3 , etc.
• heterocycle Unless otherwise specified, the term "heterocycle”, “heterocyclyl”,
• heterocycloaliphatic means monocyclic, bicyclic (fused or spiro), tricyclic (fused or spiro), or propellane ring systems in which one or more ring atoms in one or more ring members is an independently selected heteroatom and none of the individual rings in the system is aromatic. Heterocyclic rings can be saturated or can contain one or more unsaturated bonds. In some embodiments, the "heterocycle”,
• heterocyclyl has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the ring system contains 3 to 7 ring members.
• the point of attachment can be on the carbon or heteroatom.
• heteroatom means oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR* (as in N-substituted pyrrolidinyl)).
• alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.
• aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic (fused), and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms.
• aryl may be used interchangeably with the term “aryl ring”.
• heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic (fused), and tricyclic (fused or spiro) ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
• heteroaryl may be used
• heteroaryl ring or the term “heteroaromatic”.
• alkylene refers to a straight or branched hydrocarbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
• prodrug represents a compound that is transformed in vivo into a compound according to any one of the formulae listed herein. Such a transformation can be affected, for example, by hydrolysis in blood or enzymatic transformation of the prodrug form to the parent form in blood or tissue.
• Prodrugs of the compounds of the invention may be, for example, amides.
• Amides that may be utilized as prodrugs in the present invention are phenyl amides, aliphatic (C1-C24) amids, acyloxymethyl amides, ureas, carbamates, and amino acid amides.
• a compound of the invention that contains an NH group may be acylated at this position in its prodrug form.
• prodrug forms include esters, such as, for example phenyl esters, aliphatic ( -C24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters.
• esters such as, for example phenyl esters, aliphatic ( -C24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters.
• the present invention features a prodrug of any one of the formulas or compounds listed herein.
• isosteres or “bioisosteres,” as used herein, refers to compounds resulting from the exchange of an atom or group of atoms to create a new compound with similar biological properties to the parent compound.
• the bioisosteric replacement may be
• an isosteric replacement for a carboxylic acid is CONHSChialkyl or aryl)) such as CONHSC ⁇ Me.
• CONHSChialkyl or aryl a further discussion of isosterism is provided in R. Silverman, The Organic Chemistry of Drug Design and Drug Action, second edition, Elsevier Academic Press, 2004, incorporated in its entirety herein by reference.
• the present invention features a isostere of any one of the formulas or compounds listed herein.
• R group can be bonded to any carbon, or if applicable, heteroatom such as N, of that ring, including any fused ring, as valency allows.
• a CH 2 unit or, interchangeably, a methylene unit may be replaced by O, CO, S, SO, SO2, or NR; it is meant to include any CH 2 unit, including a CH 2 within a terminal methyl or methylene group.
• -CH2CH2CH 2 SH is within the definition of C1-C9 alkylene-R4 wherein up to four CH 2 units are independently replaced by O, CO, S, SO, S0 2 , or NR because the CH 2 unit of the terminal methyl group has been replaced by S.
• the analogous applies to such definitions as - CH2CH2OH, -CH2CH 2 CN, or-CH 2 CH 2 NH 2 .
• structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Where the enantiomers of a racemic mixture have been separated, but the absolute chemistry has not yet been determined, the compound's structure is depicted with a wavy line. [0058] Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Thus, included within the scope of the invention are tautomers of compounds of formulas I to Id-ii.
• CFTR is a cAMP/ATP-mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
• CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
• the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as FS08del. This mutation occurs in approximately 70 percent of the cases of cystic fibrosis and is associated with a severe disease. A more complete list of identified mutations can be found at www.cftr2.org.
• the present invention features a compound of formula I:
• Ring A is a C6-C10 aryl ring; C3-C10 cycloalkyl ring; or a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR;
• Ring B is a C3-C10 cycloalkyl ring; a C6-C10 aryl ring; or a C4-C10 heteroaryl or
• heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring C is a C6-C10 aryl ring ; a C3-C14 heteroaryl or heterocyclic ring wherein
• ring atoms are independently N, NR, O, or S; or a C3-C 10 cycloalkyl ring;
• W is O, NR, or S
• X is O or R
• Y is independently CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Z is NR or CHR
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO2 or NR; C6- C10 aryl; C3-CI0 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C 10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl ;C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 aIkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO2 or NR;
• R 3 is halo; CN; OH; CC3 ⁇ 4R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is 0, 1 , 2 or 3; o is O, 1, 2, 3, 4, or 5;
• p 0, 1, 2, or 3;
• q O, 1, 2, 3, 4, or 5;
• the compounds of the invention are of formula I and the attendant definitions, provided that: i) when ring A is indole, n is not zero and rings B and C are aryl unsubstituted by CF 3 or halo; ii) when ring A is pyrazole, n is not zero; iii) when ring A is pyridyl, ring B and ring C moieties are substituted at the 2- and 3- positions of the pyridyl ring, interchangeably; and iv) when ring A is imidazole, the ring B moiety is substituted at the 2- position of the imidazole ring.
• the compounds of the present inventions are in the form of a pharmaceutically acceptable prodrug.
• ring A is a C6-C10 aryl ring, such as a phenyl, indane, 1 ,2,3,4- tetrahydronaphthalene, or naphthalene.
• ring A is a C3-C1 1 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, such as pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, 1,2,3,4-tetrahydroquinoline, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, 2,3,4,5-tetrahydro-lH-benzo[d]azepine, 1H- benzo[d] imidazole, or imidazole ring.
• ring A is a group represented by the corresponding moieties
• ring B is a cycloalkyl ring, such as a cyclopropane, cyclobutane, cyclopentane, or cyclohexane.
• ring B is a C6-C10 aryl ring, such as a phenyl.
• ring B is a heroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, such as pyridyl, pyridine- 2(lH)-one, pyrazole, indole, indoline, thiophene, dihydrobenzofuran, tetrahydrofuran , furan, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, 3-azabicyclo[3.1.0]hexane, (lR,4R)-2-oxa-5-azabicyclo[2.2.1Jheptane, pyrrolidine, azetidine, piperidine, piperazine, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is a C6-C 10 aryl ring, such as a phenyl, indane, or naphthalene.
• ring C is a C3-C10 cycloalkyl ring, such as a cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane, or (ls,4s)- bicyclo[2.2.1]heptane.
• ring C is a C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are indpependently N, NR, O, or S, such as indole, isoindoline, indoline, pyridyl, pyrrolidine, 2,5-dihydro-lH-pyrrole, morpholine, tetrahydro-2H- pyran, tetrahydrofuran, oxetane, piperidine, piperazine, azepane, azetidine,
• ring C is a group represented by the corresponding moieties
• X is O. In some embodiments, X is NR. In some
• X is NH
• Y is O.
• Y is CRR, such as CH2, CH(C1-C6 alkyl), CH(CH 3 ), orCH(CH 2 CH 3 ).
• Y is NR, such as NH, N(C1-C6 alkynyl), or N(C1-C6 alkyl).
• (Y) 0 is a bond, O, NH, (CH 2 ) m .
• N(CH 2 CH 2 CH 3 )-CH 2 NH-CH(CH 3 ), N(CH 3 )-CH(CH 3 ), or N(CH 2 CCH)-CH 2 CH 2
• Rj is halo, CN, C 1 -C6 alkyl, C 1 -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, ⁇ 1 ⁇ 4 ⁇ , amino, amido, C3-C10 heteroaryl, and C3-CI0 hetero
• Ri is a group represented by the corresponding moieties shown in the compounds of Table I.
• R is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, CI -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 carbon atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are optionally and independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p [0084] In some embodiments, ring A is and n is 1. In some embodiments, ring A
• n is 1, and Ri is tBu
• ring A is n is l. and Ri is phenyl.
• ring A is n is 1, R
• ring A is n is 1 , Ri is tBu, and Y is O.
• ring A is pyridyl, and ring C is phenyl.
• Ri is phenyl, R ⁇ is amino, and R3 is CH 3 .
• ring A is n is 1 , and Ri is pyridyl. In some embodiments, ring A is n s i 3 ⁇ 4 R, i s pyridyl. and o is 0. In some embodiment, ring A is ring B is pyridyl, and ring C is pyrrolidine. [0086] In some embodiments, ring A is n is 1 , and R
• ring A is n is 1, R
• ring A is is 1, and Rj is cycloalkyl. In some cycloalkyl, and Y is O. In some emdodiments,
• ring A is ring B i pyridyl
• ring C is cycloalkyl.
• is cycloalkyl
• R 2 is alkoxy
• R 3 is CH 3 .
• ring A is , and n is 1. In some embodiments, ring A
• ring A is , n is 1, and R
• ring A is tBu.
• ring A is , n is 1 , Rj is phenyl, and Y is 0.
• ring A is , n is 1 , R
• ring A is ring B is pyridyl, and ring C is phenyl.
• ring A is and n is 1. In some embodiments, ring A is iiss 11,, aanndd RR
• n is l
• Ri is tBu
• ring A is n is 1
• is phenyl
• Y is O
• ring A is n is 1
• Ri is tBu
• Y is
• ring A is , ring B is pyridyl, and ring C is phenyl.
• ring A is , and n is 1. In some embodiments, ring A is , n is I , and Ri is phenyl. In some embodiments, ring A is
• n is 1
• is tBu.
• ring A is , n is 1, Ri is phenyl, and Y is O.
• ring A is n is 1, R
• ring A is ring B is pyridyl, and ring C is phenyl.
• the present invention features a compound of formula I-i:
• Ring A is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ring C is a C6-C10 aryl ring , C3-C 14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are optionally N, O, or S, or a C3-C10 cycloalkyl ring;
• X is O or NR
• Y is CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Z is NR or CHR
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or
• R 2 is halo; OH; NRR; azide; CN; CO2R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; CO 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C 10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• o isO, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3;
• q O, 1, 2, 3, 4, or 5;
• the compound of formula I-i exists as a pharmaceutically acceptable prodrug.
• ring A is a pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, or imidazole ring.
• ring A is a group represented by the corresponding moieties
• ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, thiazole, pyrrolidinone, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is phenyl, indole, cycloalkyl, pyridyl, tetrahydro-2H- pyran, azepane, tetrahydrofuran, pyrrolidine, naphthalene, piperidine, azetidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• X is O. In some embodiments, X is NR. In some
• X is NH
• Y is O. In some embodiments, Y is CH 2 . In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CH 2 CH 3 ). In some embodiments, Y is NR, such as NH, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• is halo, CN, CI -C6 alkyl, CI -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, pyrazole, or thiophene ring, or a (C1-C9 alkyleneJ-R* wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• rings arc optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3) CN, CO2H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R ⁇ is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, C 1 -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are optionally O, S, N, or NR; and a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 2 is CI, F, OH, CN, N 3 , NH 2 , NH(CH 3 ), N(CH 3 ) 2 , N(CH 3 )CH 2 CH 2 CH 3 , N(CH 3 )CH 2 CH 2 CH 2 CH 3 .
• CH 3 , CH 2 OH, CH 2 CH 3 , CH 2 CH 2 CH 3 , 0, CH 3 S0 2 , CH 3 S0 2 NH, CF 3 CONH, CH 3 CONH, CH 3 C0N(CH 3 ), tBuOCONH,
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, C6- C10 aryl, or C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• Rj is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• the compound of formula I is a compound of formula I-ii:
• Ring A is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring B is a C6-C10 aryl ring
• Ring C is a C6-C 10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are optionally N, 0, or S, or a C3-C10 cycloalkyl ring;
• X is O or NR
• Y is CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Z is NR or CHR
• Ri is halo; CN; F 3 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; CI-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; CO 2 R; C1-C6 alkyl or fluoroalkyl ;C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with 0, CO, S, SO, S0 2 or NR;
• R3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C 10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SC ⁇ R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• o is O, 1, 2, 3, , or 5;
• p is O, 1, 2, or 3;
• q isO, 1, 2, 3, 4, or 5;
• the compound of formula I-ii exists as a pharmaceutically acceptable prodrug.
• ring A is a pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, or imidazole ring.
• ring A is a group represented by the corresponding moieties
• ring B is phenyl or naphthalene.
• ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, azetidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• X is O. In another embodiment, X is NR. In some embodiments,
• X is NH
• Y is 0. In some embodiments, Y is ⁇ 3 ⁇ 4. In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CH 2 CH 3 ). In some embodiments, Y is NR, such as NH, N(C1-C6 alkynyl), or N(C1-C6 alkyl).
• is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-Ri wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH3, CN, C0 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, C 1 -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or a (Cl-C9alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, C6- C10 aryl, or C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , CO 2 H, C0 2 NH 2 , OCH 2 CH 3 , CH 2 OCH 3>
• ⁇ is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• the invention features a compound of formula la:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• Ring C is a C6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;
• X is O or NR
• Y is CRR, CO, O, S, SO, SO2, S(0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR; C6- C10 aryl; C3 -CIO heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; CI -C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-CI0 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently , S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C(3 ⁇ 4R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R; R is independently H; OH'.COjH; CO 2 CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-CI0 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, l, or 2;
• o 0, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula la exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2( l/i)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, or dihydroindene.
• ring C is is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is t t
• Y is O. In some embodiments, Y is CH 2 . In some
• Y is CH(C1-C6 alky I). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CH2CI1 ⁇ 4). In some embodiments, Y is NR, such as H, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• is halo, CN, C 1-C6 alkyl, C I-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with 0, CO, S, SO, SO or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, CO2H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R t is CH 3 , CI, F, CN, OCH3, CF 3 , CH 2 CH 3 , tBu, atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF 2 , OC(CHj) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, CI -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, 0 is 2.
• n is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• ring B is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, Rj is tBu. In some embodiments, ring B and ring C are phenyl and R
• the invention features a compound of formula Ia-i:
• Ring B is a C3-C 10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ring C is a C6-C10 aryl ring, C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;
• X is O or NR
• Y is CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fl oroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH;C0 2 H; C0 2 C1-C6 aikyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, L or 2;
• o is O, 1, 2, 3, 4, or 5;
• p 0, 1, 2, or 3;
• q 0, 1, 2, 3, 4, or 5.
• the compound of formula la-i exists as a pharmaceutically acceptable prodrug.
• ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is ,
• ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• Y is O. In some embodiments, Y is C3 ⁇ 4. In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(C13 ⁇ 4). In some embodiments, Y is CH(CH 2 CH3). In some embodiments, Y is NR, such as H, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, CO 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• K ⁇ is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 2 is CI, F, OH, CN, N 3 , NH 2 , NH(CH 3 ), N(CH 3 ) 2 , N(CH 3 )CH 2 CH 2 CH 3 , N(CH 3 )CH 2 CH 2 CH 2 CH 3 .
• CH 3 , CH 2 OH, CH 2 CH 3 , CH 2 CH 2 CH 3 , 0, CHiSCh, CH 3 S0 2 NH, CF 3 CONH, CH 3 CONH, CH 3 CON(CH 3 ), tBuOCONH,
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2l OCH 3 , OCH 2 CH 3 , OC3 ⁇ 4CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR.
• R3 is a group represented by the corresponding moieties shown in the compounds of Table I.
• R3 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CF3, CH2CH3, CH2CF3, CH2CH2CH3, OCH 2 CH(CH 3 )2, OCH(CH,)2, C0 2 H, CO2NH2, OCH2CH3, CH2OCH3, CH(CH 3 )2, CCH, CH2CONH2.
• o is 0. In some embodiments, 0 is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• the invention features a compound of formula Ia-ii:
• Ring B is a C6-C10 aryl ring
• Ring C is a C6-C 10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring; is O or NR;
• Y is CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 3 is halo; CN;a1 ⁇ 4R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, S ⁇ 3 ⁇ 4 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; CO2R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; NRR.NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; 01 ⁇ 4 ⁇ ; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is 0, I , or 2;
• o is O, 1, 2, 3, , or 5;
• p is O, 1, 2, or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ia-ii exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or naphthalene.
• ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Y is O. In some embodiments, Y is CH2. In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(C3 ⁇ 4). In some embodiments, Y is CH(CH2CH3). In some embodiments, Y is NR, such as NH, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• Ri is halo, CN, C 1 -C6 alkyl, C 1 -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, CO2H, amino, amido, C3-C 10 heteroaryl, and C3-C 10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Ri is CH 3 , CI, F, CN, CH 3 , CF 3 , CH 2 CHj, tBu,
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C 1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table I.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2 , OCH 3 , OCH2CH3, OC3 ⁇ 4CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF3, OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCHiCH ⁇ ,
• R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• the compound of formula I is a compound of formula lb:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• Ring C is a C6-C10 aryl ring, C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;
• Y is CRR, CO, O, S, SO, SO 2 , S(0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyi; C1-C6 alkoxy or
• fluoroalkoxy C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; CO 2 R; C1-C6 alkyl or fluoroalkyi; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; or a (C1-C9 alkyleneJ-R, wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR;
• Rj is halo; CN; CO 2 R; C1-C6 alkyl or fluoroalkyi; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (CI-C9 alkyleneJ-R* wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH.CC ⁇ H; CO 2 CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3; o is O, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3;
• q 0, 1, 2, 3, 4, or 5.
• the compound of formula lb exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is phenyl, indole, cycloalkyl, pyridyl, naphthalene, pyrrolidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring C is
• Y is 0. In some embodiments, Y is C3 ⁇ 4. In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CHiCH 3 ). In some embodiments, Y is NR, such as NH, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, CO 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• Ri is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Ri is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C 10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO* or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C 1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• ring B is pyridyl. In some embodiments, ring B is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, ring B is pyridyl and ring C is phenyl. In some embodiments, Y is CH 2 . In some embodiments, Y is O.
• Ri is aryl.
• are phenyl.
• ring B is pyridyl
• ring C is phenyl
• is phenyl.
• are phenyl
• Y is CH 2 .
• are phenyl, and Y is O.
• ring B is pyridyl
• ring C is phenyl
• Ri is phenyl
• Y is CH 2 .
• ring B is pyridyl
• ring C is phenyl
• is phenyl
• Y is O.
• ring C is heterocyclic.
• ring C is pyrrolodine.
• ring C is piperidine.
• ring B is pyridyl
• ring C is heterocyclic.
• ring B is pyridyl
• ring C is
• Ri is phenyl.
• ring B is phenyl
• ring C is
• R t is heteroaryl.
• ring C is pyrrolidine and Ri is heteroaryl.
• ring C is pyrrolidine and Ri is pyrrozole.
• ring B is pyridyl
• ring C is pyrrolidine
• Ri is heteroaryl.
• ring 6 is pyridyl
• ring C is heterocycloalkyl
• is cycloalkyl.
• ring B is pyridyl and Ri is cycloalkyl.
• the invention features a compound of formula Ib-i:
• Ring B is a C3-C 10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ring C is a C6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;
• Y is CRR, CO, O, S, SO, S0 2 , S(0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (CI-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; orC3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroaIkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• o is O, 1, 2, 3, 4, or 5;
• p 0, 1, 2, or 3;
• q 0, 1, 2, 3, 4, or 5.
• the compound of formula I -i exists as a pharmaceutically acceptable prodrug.
• ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is phenyl, indole, cycloalkyl, pyridyl, naphthalene, pyrrolidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• Y is O. In some embodiments, Y is C3 ⁇ 4. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CH 2 CH 3 ). In some embodiments, Y is NR, such as NH, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• R is halo, CN, C 1 -C6 alkyl, C 1 -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCHj, CN, C0 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R2 is halo, OH, CN, azide, amino, C1-C6 alky] or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR.
• R2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n
• p is 0. In some embodiments, p is 1. In some embodiments, p
• the invention features a compound of formula Ib-ii:
• Ring B is a C6-C10 aryl ring
• Ring C is a C6-C10 aryl ring, C3-CI4 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;
• Y is CRR, CO, O, S, SO, SOj, S ⁇ 0)NH or NR;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• 4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is 0, 1, 2 or 3;
• o 0, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-ii exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or napthalene.
• ring C is phenyl, indole, cycloalkyl, pyridyl, naphthalene, pyrrolidine, or dihydroindene.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• Y is O. In some embodiments, Y is CH 2 . In some
• Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH 3 ). In some embodiments, Y is CH(CH2CH 3 ). In some embodiments, Y is NR, such as NH, N(C1- C6alkynyl), or N(C1-C6 alkyl).
• is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, Cl- C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH 2 OCH 3 , CN, CO 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table I.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalky], C 1 -C6 alkoxy. or C3-C10 heteroaryi wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• o is 0. In some embodiments, o is 1. In some embodiments, o is 2.
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• the invention features a compound of formula Ib-iii:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; or C3-C10 cyclo
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• Rj is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from I to 4 ring atoms are independently 0, S, N, or NR; C3- C10 cycloalkyl; or a (CI-C9 alkylene)-R4 wherein up to four CH units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; ⁇ 1 ⁇ 4 ⁇ ; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• p 0, 1, 2, or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-iii exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkyleneJ-Rt wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH3, CN, CC3 ⁇ 4H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkyIene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2 , CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF3, OCHF 2 , OC(CHj) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, CI -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH3, CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 )2, OCH(CH 3 )2, C0 2 H, C0 2 NH 2 , OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , COjtBu, tBu,
• ⁇ is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• is phenyl, pyridine, or pyrazole, and n is 1.
• is phenyl, pyridine, or pyrazole, n is 1, R ⁇ is amino or alkyl, and p is 0 or 1.
• Ri is phenyl, pyridine, or pyrazole, n is 1, R3 is alkyl, such as methyl, and q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-iii-1 :
• Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ring C is a C3-C14 heteroar l or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, 0, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C I -C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SC ⁇ R;
• R is independently H; 0 ⁇ ; ⁇ 1 ⁇ 4 ⁇ ; C0 2 CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n i O, 1, 2 or 3;
• o is O, 1, 2, 3, 4, or 5;
• p is O, 1, 2, or 3; and q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-iii-1 exists as a pharmaceutically acceptable prodrug.
• ring B is pyridyl, pyridine-2( 1 H)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• R is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (CI-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO or NR.
• rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH3, CN, COjH, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• Ri is a group represented by the corresponding moieties shown in the compounds of Table 1.
• is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 ,
• R2 is halo, OH, CN, azide, amino, C -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S j or NR.
• R2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI. I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCrhCHCCHsk, OCH(CH 3 ) 2 , C0 2 H, C0 2 NH 2 , OCHzCHj, CH 2 OCH 3 , CH(CH 3 )2, CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , C0 2 tBu, tBu,
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole, and n is 1.
• is phenyl, pyridine, or pyrazole, n is 1
• R.2 is amino or alky I
• p is 0 or 1.
• is phenyl, pyridine, or pyrazole, n is 1,
• R 3 is alkyl, such as methyl
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-iii-2:
• Ring B is a C6-C10 aryl ring
• Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Rj is halo; CN; F S S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; CO 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; CI-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-CI0 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 4 is H; azide; CFj; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S. N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• o is O, 1, 2, , 4, or 5;
• the compound of formula Ib-iii-2 exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or naphthalene.
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring C is $
• is halo, CN, C 1 -C6 alk l, C 1 -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R 4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH3, CN, C(3 ⁇ 4H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• Ri is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R is CHj, CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 ,
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2> CHF 2l OCH 3 , 0CH 2 CH 3 , OCH 2 CH 2 CH 3 , 0CH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF2, OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CFj, CH 2 C3 ⁇ 4, CH 2 CF 3 , CH 2 CH 2 CHj, OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C(3 ⁇ 4H, C ⁇ 1 ⁇ 4NH 2 , OCH2CH3, CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , CC ⁇ CHs, -CH 2 N(CH 3 ) 2 , C0 2 tBu, tBu,
• n is 0. In some embodiments, n is 1. In some
• n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R 2 is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R3 is alkyl, such as methyl, and q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-iv:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR;
• R 3 is halo; CN; CO2R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; CI-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3- CIO cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SC3 ⁇ 4 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; CO2R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is indcpendenUy H; OH; C0 2 H; CO2CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C 10 cycloalkyl; p is O, 1, 2, or 3; and q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-iv exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2(l )-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• Ri is a phenyl, thiophene, pyridine, or pyrazole.
• is a group represented by the corresponding moieties shown
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO ? or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 2 is CI, F, OH, CN, N 3 , NH 2 , NH(CH 3 ), N(CH 3 )2.
• N(CH,)CH 2 CH 2 CH 3 , N(CH 3 )CH 2 CH 2 CH 2 CH 3 , CH 3 , CH 2 OH, CH 2 CH 3 , CH 2 CH 2 CH 3 , 0, CH3SO2, C3 ⁇ 4S0 2 NH, CF3CONH, CH3CONH, CH 3 CON(CH 3 ), tBuOCONH,
• (CH 3 ) 2 CHOCONH, CH(CH 3 )2, CHF 2 , OCH 3) OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF3, OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR.
• R$ is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 ⁇ 4 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CF3, CH 2 CH 3 , CH2CF3, CH2CH2CH3, OCHiCH(CH 3 )2, OCH(CH 3 ) 2 , CO2H, CO2NH2, OCH2CH3, CH2OCH3, CH(CH 3 ) 2 , CCH, CH2CONH2, CO2CH3, -CH 2 N(CH 3 )2, C0 2 tBu, tBu,
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• R 1 is phenyl, pyridine, or pyrazole.
• is phenyl, pyridine, or pyrazole
• R 2 is amino or alkyl
• p is 0 or 1.
• Ri is phenyl, pyridine, or pyrazole
• R 3 is alkyl, such as methyl
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-iv- 1 :
• Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CHj units are independently replaced with O, CO, S, SO, S0 2 or NR;
• Rv is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 hcteroaryl or beterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; is O, 1, 2, or 3; and
• q is O, 1, 2, 3, 4, or 5.
• ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• the compound of formula Ib-iv-1 exists as a pharmaceutically acceptable prodrug.
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring C is
• R ( is a phenyl, thiophene, pyridine, or pyrazole.
• Ri is a group represented by the corresponding moieties shown
• R 2 is halo, OH, CN, azide, amino, C 1 -C6 alkyl or fluoroalkyl, CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR or a (C1-C9 aIkylene)-R wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C0 2 H, COjNH,, OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , COjCFfc, -03 ⁇ 4N(CH3)2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole.
• is phenyl, pyridine, or pyrazole
• R? is amino or alkyl
• p is 0 or 1.
• Ri is phenyl, pyridine, or pyrazole
• 3 is alkyl, such as methyl
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-iv-2:
• Ring B is a C6-C10 aryl ring
• Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;
• Ri is C6-C10 aryl or C3-CI0 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• R 2 is halo; OH; NRR; azide; CN; CO2R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; CI-C6 aikynyl; C6-C10 ar l; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 aikynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 aikynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; p is 0, 1, 2, or 3; and
• q 0, 1, 2, 3, 4, or 5.
• the compound of formula I -iv-2 exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or napthalene.
• ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.
• ring C is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring C is
• is a phenyl, thiophene, pyridine, or pyrazole.
• is a group represented by the corresponding moieties shown
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R* wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 )2, CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHFj, OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R3 is CI, I, deuterium, F, CN, CH3, OH, OC3 ⁇ 4, CF 3 , CH 2 C3 ⁇ 4, CH 2 CF3, CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 >2, COjH, C02NH 2 , OCH 2 CHj, CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , C0 2 tBu, tBu,
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• is phenyl, pyridine, or pyrazole.
• is phenyl, pyridine, or pyrazole
• R? is amino or alkyl
• p is 0 or 1.
• Ri is phenyl, pyridine, or pyrazole
• R 3 is alkyl, such as methyl
• q is 1 , 2, 3, or 4.
• the invention features a compound of formula Ib-v:
• Ring B is a C6-C 10 aryl ring or C3-C 10 heteroaryl or heterocyclic ring wherein
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO 2 or NR; C6- C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; CO 2 R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with 0, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C 10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-v exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2( ll ⁇ -one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• is halo, CN, CI-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alky!ene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, SO2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH 3 , CN, CO 2 H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• is a group represented by the corresponding moieties shown in the compounds of Table I.
• R 2 is halo, OH, CN, azide, amino, C 1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C ⁇ 1 ⁇ 4H, C0 2 NH 2 , OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , C0 2 tBu, tBu,
• n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, R
• the invention features a compound of formula Ib-v- 1 :
• Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are
• Ri is halo; CN; F 5 S; SiR 3 ; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO 2 or NR; C6- CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyleneJ-R, wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C 10 aryl; C3-C 10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• p is O, 1, 2, or 3;
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-v-1 exists as a pharmaceutically acceptable prodrug.
• ring B is pyridyl, pyridine-2(l /)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring 6 i s
• is halo, CN, C1-C6 alkyl, C 1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to fourCH2 units are independently replaced with O, CO, S, SO, SO 2 or NR, wherein all rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH 2 OH, CH2OCH3, CN, COiH, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.
• Ri is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Rj is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 ,
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently 0, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2> C0 2 H, 01 ⁇ 4 ⁇ 2 , OCH 2 CH 3 , CH 2 OCH 3 , CHCCH ⁇ , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , CO Bu, tBu, > X>. 3 ⁇ 4" ° ⁇ Q. ⁇ ° HQ ⁇ - cn ⁇ ⁇
• n is 0. In some embodiments, n is 1. In some
• n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• R t is phenyl, pyridine, or pyrazole, and n is 1.
• is phenyl, pyridine, or pyrazole, n is 1
• R* is amino or alkyl
• p is 0 or 1.
• R ⁇ is phenyl, pyridine, or pyrazole, n is 1,
• R3 is alkyl, such as methyl
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-v-2:
• Ring B is a C6-C10 aryl ring
• Ri is halo; CN; F 5 S; SiR 3 ; OH; RR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or
• fluoroalkoxy C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR; C6- CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 2 is halo; OH; NRR; azide; CN; C0 2 R; C1-C6 alky] or fluoroatkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyleneJ-R* wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alky!ene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R is H; azide; CFj; CHF 2 ; OR; CCH; CO 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; CO 2 CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C 10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; n is O, 1, 2 or 3;
• p is O, 1, 2, or 3; and q is O, 1, 2, 3, 4, or 5.
• the compound of formula I -v-2 exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or napthalene.
• is halo, CN, C 1 -C6 alkyl, CI -C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO?
• is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Rj is CH 3 , CI, F, CN, OCH 3 , CF 3 , CH 2 CH 3 , tBu,
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 aJkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 ) 2) CHF 2 , OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OCH 2 CH 2 CH(CH 3 )2, OCF 3 , OCHF2, OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• R 3 is halo, CN, C1-C6 alky] or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR.
• R3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R3 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CFj, CH2CH3, CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C0 2 H, C0 2 NH 2 , OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2 , C ⁇ 1 ⁇ 4tBu, tBu,
• n is 0. In some embodiments, n is 1. In some
• n is 2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole, and n is 1.
• Rj is phenyl, pyridine, or pyrazole, n is 1, R is amino or alkyl, and p is 0 or 1.
• the invention features a compound of formula Ib-vi:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• R 3 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C 1 -C9 alky]ene)-R « wherein up to four Cl1 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• F is H; azide; CF 3 ; CHF 2 ; OR; CCH; CO2R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; CO2H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O. S, N, or NR; or C3-C10 cycloalkyl; p is 0, 1, 2, or 3; and
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-vi exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• R is a phenyl, thiophene, pyridine, or pyrazole.
• Rj is a group represented by the corresponding moieties shown
• R2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 aIkylene)-R4 wherein up to four CH 2 units are independently replaced with 0, CO, S, SO, S0 2 or NR.
• R2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Rj is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C 10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independentl O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH , OH, OCHj, CF 3 , CH2CH3, CH2CF3, CH2CH2CH3, OCH2CH(CH 3 ) 2 , OCH(CH 3 )2.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole.
• is phenyl, pyridine, or pyrazole
• R2 is amino or alkyl
• p is 0 or 1.
• R ( is phenyl, pyridine, or pyrazole
• R 3 is alkyl, such as methyl
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-vi- 1 : (R 2 )p
• Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring
• atoms are independently 0, S, N, or NR;
• Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;
• R 3 is halo; CN; CO 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R_) wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R; is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N law or NR; or C3-C10 cycloalkyl; p is 0, 1, 2, or 3; and
• q is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-vi- 1 exists as a pharmaceutically acceptable prodrug.
• ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza- indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• is a phenyl, thiophene, pyridine, or pyrazole.
• is a group represented by the corresponding moieties shown
• R 2 is halo, OH, CN, azide, amino, C 1 -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R 4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCHj, CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C0 2 H, C0 2 NH 3 , OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -Ctfe CCH ⁇ , C(1 ⁇ 4tBu, tBu,
• ⁇ is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• is phenyl, pyridine, or pyrazole.
• Ri is phenyl, pyridine, or pyrazole, Ri is amino or alkyl, and p is 0 or 1.
• is phenyl, pyridine, or pyrazole, R3 is alkyl, such as methyl, and q is 1 , 2, 3, or 4.
• the invention features a compound of formula Ib-vi-2:
• Ring B is a C6-C10 aryl ring
• Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or R;
• R 2 is halo; OH; NRR; azide; CN; C ( 1 ⁇ 4R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyleneJ-R* wherein up to four C3 ⁇ 4 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-CI0 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C 10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; CO2CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl; is O, 1, 2, or 3; and
• q is O, 1, 2, 3, , or 5.
• the compound of formula Ib-vi-2 exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl or napthalene.
• Ri is a phenyl, thiophene, pyridine, or pyrazole.
• is a group represented by the corresponding moieties shown
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alk lene)-R wherein up to four CH2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table I.
• R 3 is halo, CN, C 1 -C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 3 is CI, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF 3 , CH 2 CH 3 , CH 2 CF 3 , CH 2 CH 2 CH 3 , OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C0 2 H, C0 2 NH 2 , OCH 2 CH 3 , CH 2 OCH 3 , CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CHzNiCH ⁇ , C0 2 tBu, tBu, 3 ⁇ 4 3 ⁇ 4 ° A 0H O* 63 ⁇ 4
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• Ri is phenyl, pyridine, or pyrazole. In some embodiments, Ri is phenyl, pyridine, or pyrazole, Ri is amino or alkyl, and p is 0 or 1. In some embodiments, R
• the invention features a compound of formula Ib-vii:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• ring atoms are independently O, S, N, or NR;
• R 2 is halo; OH; NRR; azide; CN; CQjR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-CI0 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R
• R4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0 2 R;
• R is independently H; OH; C0 2 H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 5 is halo; CN; C0 2 R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; CI-C6 alkoxy or fluoroalkoxy; or C6-C 10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkyleneHl* wherein up to four CH 2 units are independently replaced with 0, CO, S, SO, S0 2 or NR;
• p is O, 1, 2, or 3;
• q O, 1, 2, 3, 4, or 5;
• r is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-vii exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring B is
• R 2 is halo, OH, CN, azide, amino, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• Rj is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR.
• R 3 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R3 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CF 3 , CH2CH3, CH2CF3, CH2CH2CH3, OCH 2 CH(CH 3 )2, OCH(CH 3 ) 2 , C0 2 H, C0 2 NH 2 , OCH2CH3, CH2OCH3, CH(CH 3 )2, CCH, CH2CONH2, CO2CH3, -CH 2 N(CH 3 ) 2 , C0 2 tBu, tBu,
• R3 is ha ,locut,, CN-, C ⁇ l -C6. alkyl or fluoroalkyl, CI -C6 alkoxy, or C3-C10 heteroary] wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• R5 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R 5 is Cl, I, deuterium, F, CN, CH 3 , OH, OCH 3 , CF3, CH2CH3, CH2CF3, CH2CH2CH3, OCH 2 CH(CH 3 ) 2 , OCH 2 C(CH 3 ) 3 OCH(CH 3 ) 2 , CC3 ⁇ 4H, CC ⁇ NHz, OCH 2 CH 3 , CH2OCH3, CH(CH 3 ) 2 , CCH, CH 2 CONH 2 , CO2CH3, -CH 2 N(CH 3 ) 2 , CC ⁇ tBu, tBu,
• r is 0. Inuß some eambodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5.
• R5 is halo or alkoxy.
• R 2 is amino or alkyl
• Rs is halo or alkoxy
• r is 1 or 2
• p is 0 or 1.
• R$ is halo or alkoxy
• R3 is alkyl, such as methyl
• r is 1 or 2
• q is 1 , 2, 3, or 4.
• the invention features a compound of formula Ib-viii:
• Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein
• I to 4 ring atoms are independently O, S, N, or NR;
• R 2 is halo; OH; NRR; azide; CN; C ⁇ 3 ⁇ 4R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; CI-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units arc independently replaced with O, CO, S, SO, SO2 or NR;
• R 3 is halo; CN; O- R; C1-C6 alkyl or fluoroalkyl; CI -C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH 2 units are independently replaced with O, CO, S, SO, S0 2 or NR;
• R 4 is H; azide; CF 3 ; CHF 2 ; OR; CCH; C0 2 R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO2R; R is independently H; OH; CO2H; C0 2 C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;
• R 5 is halo; CN; CO2R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3- C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with 0, CO, S, SO, S0 2 or NR;
• q O, 1, 2, 3, 4, or 5;
• r is O, 1, 2, 3, 4, or 5.
• the compound of formula Ib-viii exists as a pharmaceutically acceptable prodrug.
• ring B is phenyl, pyridyl, pyridine-2( lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.
• ring B is a group represented by the corresponding moieties shown in the compounds of Table 1.
• ring B is
• R 2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R* wherein up to four CH 2 units are independently replaced with O, CO, S, SO, SO2 or NR.
• R 2 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• (CH 3 ) 2 CHOCONH, CH(CH 3 fc, CHF 2 , OCH 3 , OCH 2 CH 3 , OC ⁇ CH ⁇ Hs, OCH 2 CH 2 CH(CH 3 ) 2 , OCF 3 , OCHF 2 , OC(CH 3 ) 3 , OCH 2 CH 2 tBu, NHCH(CH 3 )(CH 2 CH 2 CH 3 ), OCH(CH 3 ) 2 ,
• j is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• Rj is a group represented by the corresponding moieties shown in the compounds of Table 1.
• R3 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CF,, CH2CH3, CH2CF3, CH2CH2CH3, OCH 2 CH(CH 3 ) 2 , OCH(CH 3 ) 2 , C0 2 H, CO2NH2, OCH2CH3, CH2OCH3, CH(CH 3 ) 2 , CCH, CH2CONH2, CO2CH3, -CH 2 N(CH 3 )2, COitBu, tBu,
• R 3 is halo, CN, C 1-C6 alkyl or fluoroalkyl, C 1 -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.
• p is 0. In some embodiments, p is 1. In some embodiments, p is 2.
• R5 is a group represented by the corresponding moieties shown in the compounds of Table 1.
• 5 is CI, I, deuterium, F, CN, CH3, OH, OCH3, CF 3 , CH2CH3, CH 2 CF 3 , CH 2 CH 2 CHj, OCH 2 CH(CH 3 )2, OCH 2 C(CH 3 ) 3 OCHiOfcfc, CCfeH, CO2NH2, OCH 2 CH 3 , CH 2 OCH 3 , CH(C3 ⁇ 4) 2 , CCH, CH 2 CONH 2 , C0 2 CH 3 , -CH 2 N(CH 3 ) 2) CO ⁇ tBu, tBu,
• r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5.
• R$ is halo or alkoxy.
• R 2 is amino or alkyl
• R 5 is halo or alkoxy
• r is 1 or 2
• p is 0 or 1.
• R 5 is halo or alkoxy
• R 3 is alkyl, such as methyl
• r is 1 or 2
• q is 1, 2, 3, or 4.
• the invention features a compound of formula Ib-ix:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyridine Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pyrrole Compounds (AREA)
• Quinoline Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Indole Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (33)

Applications Claiming Priority (6)

Publications (1)

Family

ID=55631997

Family Applications (1)

Country Status (28)

Cited By (45)

Families Citing this family (50)

Citations (48)

Family Cites Families (221)